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Background: The AS04-adjuvanted bivalent L1 virus-like-particle (VLP) vaccine (Cervarix™) against infection with
human papillomavirus (HPV) types 16/18 holds great promise to prevent HPV16/18 infections and associated
neoplasias, but it is important to rule out significant co-factors of the neoplasias like smoking.
Methods: We conducted a pilot study to compare the quantity and quality of HPV16/18 antibody response at
baseline and 7 months post vaccination in 104 non-smoking and 112 smoking female participants vaccinated at 0,
1 and 6 months with Cervarix™ (55 and 48 study participants) or with Hepatitis A vaccine (HAVRIX™) (48 and 64
participants, respectively). These 216 women were a sub-sample of 4808 baseline 16- to 17-year old Finnish women
initially enrolled in the double-blind, randomized controlled phase III PATRICIA trial. Following end-of-study unblinding
in 2009 they were randomly chosen out of all the participants of the three major Finnish PATRICIA study sites in the
Helsinki metropolitan area (University of Helsinki, N = 535, and Family Federation Finland, N = 432) and Tampere
(University of Tampere, N = 428). Following enrolment, serum samples were collected at month 0 and month 7 post
1st vaccination shot, and were analysed for levels and avidity of IgG antibodies to HPV16 and HPV18 using standard
and modified (4 M urea elution) VLP ELISAs.
Results: We found that at month 7 post vaccination women who smoked (cotinine level > 20 ng/ml) had levels of
anti-HPV16/18 antibodies comparable to those of non-smoking women. Low-avidity HPV16/18 IgG antibodies were
observed in 16% of the vaccinated women, and active smoking conferred a three-fold increased risk (95% CI 1.0-9.3) of
having the low-avidity antibodies.
Conclusion: Our data suggest that while smoking does not interfere with the quantity of vaccine-induced peak IgG
levels, it may affect the avidity of IgG induced by HPV16/18 vaccination.
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Infection with high-risk (hr) types of human papillomavi-
rus (HPV) is the major cause of cervical cancer (CC) [1].
The necessary role of hrHPV infections in CC and other
HPV related cancers provides an opportunity to signifi-
cantly reduce associated disease burden by prophylactic
vaccines [2] with proper coverage/herd immunity [3,4].
Important determinants of vaccine efficacy are the quan-
tity and quality of the B-cell response. The AS04-
adjuvanted HPV16/18 L1 virus-like-particle (VLP) vaccine
induces high titer antibodies in adolescent and young
women and men [5,6], able to neutralize the virus [7,8], and
detectable up to 8.4 years post vaccination [9]. The immune
responses are, however, not homogenous, eg. a proportion
of HPV-16/18 vaccinated women, those with significantly
lower serum antibody levels, had no detectable cervical
antibodies 4 years post vaccination [6]. Furthermore, not all
vaccinees develop high avidity antibodies, and the avidities
and levels of the neutralizing antibodies correlate only
moderately [10]. High avidity of HPV vaccine induced anti-
bodies may indicate successful priming for long-term mem-
ory responses as previously suggested by Scherpenisse [11].
Smoking women have an impaired humoral immune re-
sponse to HPV16/18 infections [12]. Smoking has also been
associated with decreased clearance of persistent HPV le-
sions [13]. Furthermore, epidemiological studies have indi-
cated that tobacco smoking is an independent risk factor
for CC [14]. The effect of smoking on vaccine efficacy and
effectiveness has been studied in influenza vaccine trials
[15], but its influence on the HPV vaccine response is un-
known. In this pilot study, we compared the quantity and
quality of HPV16/18 antibody responses at baseline and
seven months post vaccination in smokers and non-
smokers vaccinated with three doses of AS04-adjuvanted
HPV16/18 VLP vaccine or Hepatitis A vaccine.
Methods
Study participants
Enrolment for the PApilloma TRIal against Cancer In
young Adults (PATRICIA (study trial number −580299/
008)) study took place from April 2004 to May 2005 in
Finland [16]. Healthy women aged 16–17 years were eli-
gible to participate in the Finnish arm of this study with
no exclusion criteria with regard to lifetime number of
sexual partners before study enrolment [16,17]. Individuals
with intact cervix, and agreeing to adequate contraception
(barrier methods in combination with a spermicide, or
hormonal contraception) over the vaccination period were
eligible for inclusion. Exclusion criteria were limited to a
history of colposcopy, pregnancy or breastfeeding, as well
as autoimmune diseases and immunodeficiency. Informed
consent was obtained from each participant at study base-
line including later linkage to the Finnish Maternity
Cohort (FMC) for the identification of serial serumsamples post vaccination. The study protocols, recruit-
ment material and informed consent forms were ap-
proved by the Finnish National and Pohjoispohjanmaan
Sairaanhoitopiirin ethical review committees, and the
retrieval of serum samples from the FMC repository by
the National Institute for Health & Welfare.
Study design
The PATRICIA study was a phase III double-blind, ran-
domized controlled trial. In Finland, a total of 4,808 partici-
pants, were randomized in a 1:1 fashion with an internet-
based centralized randomisation system, received either the
AS04-adjuvanted HPV16/18 vaccine ((GlaxoSmithKline Bi-
ologicals, Rixensart, Belgium), (Each dose of HPV-16/18 L1
VLP AS04-adjuvanted candidate vaccine (Cervarix™)
contained 20 mg each of HPV16 and HPV18 L1 pro-
teins self-assembled as VLPs and adjuvanted with AS04
(50 μg 3-O-desacyl-40-monophosphoryl lipid A [MPL]
and 500 μg aluminium hydroxide)) or, a control hepa-
titis A vaccine ((GSK Biologicals), Each dose of the con-
trol hepatitis A vaccine contained 720 ELISA units (EU)
of inactivated hepatitis A antigen and 0 · 5 mg alumin-
ium hydroxide)) to provide a health benefit for all par-
ticipants and ensure double-blinding. Allocation of
treatment numbers was stratified by study site and age.
A random sample of 216 study participants with un-
blinded individual vaccine allocation were selected for this
study from the three largest Finnish study sites: Finnish
Family Federation, Helsinki (432 participants, PI DA),
University of Helsinki, Helsinki (535 participants. PI JP)
and University of Tampere, Tampere (428 participants, PI
ML). Serial serum samples accounting for the FMC-based
long-term follow-up were available for 51, 97 and 103 par-
ticipants, respectively, altogether for 251 of the total 1395
participants. The vaccines were supplied double-blinded
in identical 0 · 5 ml pre-filled syringes and administered
into the deltoid muscle on a 0, 1, and 6-month schedule.
Serologic evaluation
Blood samples from the study participants were collected at
baseline and at months 7 post vaccination, and an aliquot
of each sample was stored at the National Institute for
Health and Welfare laboratory in Oulu, Finland. Baseline
and month 7 post vaccination trial serum samples were
evaluated for HPV16 and HPV18 antibodies using a type-
specific enzyme-linked immunosorbent assay (ELISA) as
described [18-20]. Dilutions 1/30, 1/300 and 1/3000 were
used to identify the linear part of the absorbance reactions
for expression of the results as OD values.
Avidity measurement
The avidity of IgG antibodies to HPV16 and HPV18 was
evaluated in the HPV vaccine group (n = 103) using
modified VLP ELISAs [21] Namujju et al. unpublished,
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GSK biologicals, Rixensart, Belgium). First, we screened
the HPV16/18 vaccine induced antibodies for low avidity
by single-dilution methods, using in parallel 4 M urea or
1 M ammonium thiocyanate as chaotropic agents. The
month 7 post vaccination samples were diluted 1:1000
in assay diluent (PBS + 10% fetal bovine serum). Each
sample was added in duplicate to a plate, one well in the
plate was washed with PBS + 0.05% Tween 20 (PBST),
and another well in the plate with either of the chaotro-
pic agents. Blank well (assay diluent), negative and posi-
tive control pools for HPV6/11/16/18/31/33/45 natural
infection derived antibodies, and acute-immunity (ob-
tained from seroconverters within 6 months of natural
infection) pools for HPV16 or HPV18 antibodies diluted
1:30 were included in each plate. After 2-hour incuba-
tion at room temperature (RT) the plates were washed
three times with PBST and then (200 ul of ) PBST was
added in half of the plate, and (200 ul of ) 4 M urea or
1 M ammonium thiocyanate in the other half for 15 mi-
nutes. The plates were again washed two times with
PBST, after which the wells treated with the chaotropic
reagents were rinsed extra two times with PBST.
Thereafter the standard VLP ELISA procedures was
followed [21]. The avidity index (AI) was calculated
using the formula optical density (OD) of the
chaotrope-treated well/OD of the PBST-treated well) ×
100. The cut-off for low avidity (40%) was the mean + 3
standard deviations of acute- immunity controls.
Samples with results of low avidity in the single-
dilution screening test were further analyzed by a
serum titration approach [21-23], Namujju et al. un-
published, albeit using 4 M urea rather than 6 M urea.
The samples were serially diluted at four fold steps; A)
1:100, B) 1:400, C) 1:1600, D) 1:6400 and E) 1:25600.
After 2-hour incubation at RT, one half of the plate
was washed with 4 M urea, and another half with
PBST. Thus, from each sample two IgG-end-point ti-
tres at a cut-off of 0.200 (urea +/ urea -) were ob-
tained. Their ration – representing IgG avidity – was
calculated with curve-fitting software [24].Cotinine measurements
Serum samples were measured for cotinine using an im-
munoassay method (OraSure Technologies, Bethlehem,
PA, USA) carried out as a quantitative assay based on the
competition between free cotinine in the sample and
horseradish peroxidase-labeled cotinine. Cotinine was
quantified spectrophotometrically at 450 nm and 630 nm
relative to a standard curve. The assay’s sensitivity is 95%–
97% and specificity 99%–100% [25,26]. A cotinine level of
20 ng/ml was used as an indicator of an active smoker, ac-
cording to the manufacturer.Statistical analyses
The pilot immunoanalyses included women who met eli-
gibility criteria, received all vaccination shots and com-
plied with the protocol procedures. Seropositivity rates of
HPV16 and HPV18 were calculated. The Mann–Whitney
test was used to compare the mean absorbances of anti-
HPV16 and HPV18 antibodies between non-smokers and
smokers in vaccine and control groups. For each antigen
the mean absorbance level and standard deviation (±SD)
were reported. Kappa-coefficients were calculated to
evaluate consistency of the two parallel screening methods
for the detection of low avidity HPV16/18 antibodies. The
proportions of low-avidity HPV16 and HPV18 antibodies
by the titration method were calculated, and the crude
odds ratios (OR) with 95% confidence interval (CI) of low-
avidity antibodies according to smoking status were esti-
mated using logistic regression. All statistical analyses
were performed with SPSS 16.0 and STATA 8 (Stata
Corp., College, Texas, USA).
Results
Demographic characteristics of the entire vaccinated co-
hort have been published previously [17]. In the present
pilot study, we included 216 Finnish trial participants
with unblinded vaccine codes, and who had complied
with the full three-dose vaccination schedule. Out of 103
participants in the HPV16/18 vaccine group, 46.6% (48)
were smokers compared to 56.6% (64) in the control
group (n = 113).
Mean anti-HPV16 and HPV18 antibody levels at month
7 post-vaccination were very high in the HPV16/18 vac-
cine group as compared to the control (HAV vaccine)
group or to baseline (Table 1). When the anti-HPV16 and
anti-HPV18 antibody levels between non-smokers and
smokers were compared, the mean absorbance of anti-
HPV16 antibodies was 1.97 (±0.78) among non-smokers
and 1.88 (±0.73) among smokers. Mean absorbance of
anti-HPV18 antibodies was 1.44 (±0.85) among non-
smokers and 1.36 (±0.76) among smokers. The observed
differences between the smokers and non-smokers were
not statistically significant (Table 1).
We also evaluated in the HPV16/18 vaccine group the
quality, i.e. the avidity of vaccine-induced HPV16 and
HPV18 antibodies. In the screening phase, where 4 M
urea or 1 M NH4CSN were used as chaotropic agents,
reasonably high kappa-coefficients of consistency for pres-
ence of low avidity HPV antibodies (0.7 for low avidity
HPV16 antibodies; 0.6 for low avidity HPV18 antibodies)
were observed in 27 and 17 individuals, respectively.
By the reference approach (titration method using 4 M
urea), 13 out of the 27 samples with screen-detected
HPV16 samples were confirmed to have low avidity,
whereas three of the 17 screen-detected HPV18 samples
had low-avidity HPV18 antibodies (Table 2). Eleven of
Table 1 Comparison of mean absorbance level and mean antibody titers with standard deviation (SD) of anti-HPV16
and HPV18 antibodies between non-smokers and smokers by vaccination group
HPV vaccine (n = 103) HAV vaccine (n = 113)
Non-smokers (n = 55)*
mean (±SD)
Smokers (n = 48)*
mean (±SD)
p-value† Non-smokers (n = 49)*
mean (±SD)
Smokers (n = 64)*
mean (±SD)
p-value†
HPV16
Antibody absorbance
Baseline 0.12 (±0.08) 0.29 (±0.52) 0.2 0.21 (±0.43) 0.18 (±0.29 ) 0.9
Month 7 1.97 (±0.78) 1.88 (±0.73) 0.4 0.01 (±0.04) 0.01 (±0.02) 0.7
HPV18
Antibody absorbance
Baseline 0.07 (±0.06) 0.18 (±0.008) 0.1 0.1 (±0.08) 0.10 (±0.14) 0.8
Month 7 1.44 (±0.85) 1.36 (±0.76) 0.6 0.01(±0.03) 0.01 (±0.03) 0.7
*Non-smokers (Cotinine <20 ng/ml) and smokers (cotinine > =20 ng/ml).
†p-value derived from Mann–Whitney test to evaluate mean absorbance difference between non-smokers and smokers.
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were smokers. They tended to have an increased risk of
having low avidity HPV16/18 antibodies (OR 3.0, 95%
confidence interval (1.0-9.3) (Table 2).
Discussion
Evaluating the influence of HPV co-factors, particularly to-
bacco smoking, in the induction of robust post-vaccination
anti-HPV immune response is timely [2]. We found that
vaccinated young women, who smoked had similar levels
of anti-HPV16 and HPV18 antibodies compared to vacci-
nated, non-smoking women 7 months post-vaccination,
whereas the avidity of HPV16/18 antibodies might be infer-
ior in smokers.
In contrast to natural HPV infection, a prophylactic cer-
vical cancer vaccine should induce long-term immune re-
sponse with high and sustained local and systemic
antibody levels [27]. The adjuvanted HPV16/18 induces
significantly increased humoral response to the vaccine
antigens [28]. In addition to 100% seroconversion rates,
extremely high antibody levels following Cervarix™ vaccin-
ation have been evident since the interim analysis of theTable 2 Detection of persistent low avidity HPV16 or HPV18
Low avidity (= < 40%)
HPV16
Non-smokers (n = 55) 4 (31%)
Smokers (n = 48) 9 (69%)
HPV18
Non-smokers (n = 55) 1 (33%)
Smokers (n = 48) 2 (67%)
HPV16/18
Non-smokers (n = 55) 5 (31%)
Smokers (n = 48) 11 (69%)
*Exact value = 0.95, and 40% is the cut-off of low avidity.PATRICIA study, a large phase III trial of the AS04-
adjuvanted bivalent HPV16/18 vaccine [16,17,29]. The
geometric titers of vaccine induced antibodies against both
HPV16 or HPV18 antigens are substantially higher and
longer lasting than those in natural HPV16/18 infections
at all time points post vaccination/infection [9,30].
Our pilot study in young women demonstrated no
significant quantitative differences in vaccine-induced
humoral immune response to HPV16/18 L1 VLPs
among smokers compared to nonsmokers. The propor-
tion of smoking women with apparently low avidity
HPV16 antibodies was, however, approximately two
times higher than in non-smoking women. Previous
studies on HPV16/18 vaccine induced (maturation of )
antibody avidity disagree on the existence of low-
avidity antibodies [10,11,31]. In those studies con-
founding factors, e.g., differences in laboratory methods
or smoking have not been considered. The applied
chaotropic agent concentrations, re-optimized in our
lab, had a minimal effect on the performance of the
HPV16/18 VLP antigens in the standard ELISA assay
(Namujju et al. unpublished).antibodies at month 7 stratified by smoking status
High avidity (>40%) OR, 95% CI
51 (57%) 1
39 (43%) 2.9 (0.8-10.3)
54 (54%) 1
46 (46%) 2.8 (0.2-31.6)
50 (57%) 1
37 (43%) 3.0 (1.0*-9.3)
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cation, has been shown to have an adverse effect on im-
mune response to natural HPV16/18 infections among
young women followed-up for more than 5 years [12]. Al-
though the underlying mechanism is unclear, researchers
have demonstrated reduction in cervical density of Lang-
erhans cells among smokers [32,33]. Tobacco smoking has
also been associated with an increased probability of ac-
quisition and a decreased probability of clearance of HPV
infection [34,35] as well as decreased clearance of cervical
lesions [13].
Cotinine is a highly sensitive and specific marker of
current active or passive exposure to tobacco smoke
[36-38]. The use of serum cotinine rather than question-
naire data integrates a number of aspects of the expos-
ure including tobacco composition, uptake, distribution,
and individual differences in metabolism [38]. Further-
more, it is the inhaled dose of tobacco smoke that is dir-
ectly related to the development of tobacco-related
disorders [26]. Thus, biochemical assessment of tobacco
exposure underlines the validity of our observations.
Duration of HPV vaccine induced immune response
and its sustained efficacy in preventing HPV infection
and cervical neoplasia are under close surveillance [2].
Some studies have shown that vaccine induced antibody
levels decline with time. Although this has been sug-
gested also for the bivalent HPV16/18 vaccine we have
not observed it in our current study due to the short
duration. In a study by Olsson et al. [39] it was sug-
gested that although the HPV18 antibodies declined over
time, the vaccinees remained protected, pointing to the
importance of factors other than antibody levels in long-
term vaccine protection. Sustainable, high avidity IgG re-
sponse could be a surrogate marker or indirect indicator
of T-cell help post-vaccination, which may or may not
be affected by smoking habit. Our study was limited by
the small numbers of study participants.
Conclusion
Our pilot results suggest that smoking may not interfere
with the quantity, but affects the quality of HPV16/18
vaccine-induced peak IgG antibodies. Our findings war-
rant further large studies on the quality and duration of
HPV16/18 vaccine induced antibody response.Competing interests
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